Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life

Human Gene Therapy

Volumn 16, Issue 5, 2005, Pages 584-593

  Peng, Shiwen ^a   Kim, Tae Woo ^a,b   Lee, Jin Hyup ^a   Yang, M U ^a   Liangmei, H E ^a   Hung, Chien Fu ^a   Wu, T C ^a,c  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b Korea Research Institute of Chemical Technology   (South Korea)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD40 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN P 15095; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN BAK; PROTEIN BAX; RECOMBINANT PROTEIN; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL BASED GENE THERAPY; CELL SURVIVAL; CONTROLLED STUDY; DENDRITIC CELL; DOWN REGULATION; DRUG EFFECT; DRUG POTENCY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TUMOR; WART VIRUS; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DENDRITIC CELLS; DOWN-REGULATION; GENE EXPRESSION REGULATION; HUMANS; LYMPHOCYTE ACTIVATION; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; PEPTIDES; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; VACCINATION; VIRAL VACCINES;

EID: 19644396618     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2005.16.584     Document Type: Article

References (28)

1. CERUNDOLO, V., HERMANS, I.F., and SALIO, M. (2004). Dendritic cells: A journey from laboratory to clinic. Nat. Immunol. 5, 7-10.
2. DEGLI ESPOSTI, M., and DIVE, C. (2003). Mitochondrial membrane permeabilisation by Bax/Bak. Biochem. Biophys. Res. Commun. 304, 455-461.
3. ENGLEMAN, E.G. (2003). Dendritic cell-based cancer immunotherapy. Semin. Oncol. 30, 23-29.
4. FELTKAMP, M.C., SMITS, H.L., VIERBOOM, M.P., MINNAAR, R.P., DE, J.B., DRIJFHOUT, J.W., TER, S.J., MELIEF, C.J., and KAST, W.M. (1993). Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23, 2242-2249.
5. FIGDOR, C.G., DE VRIES, I.J., LESTERHUIS, W.J., and MELIEF, C.J. (2004). Dendritic cell immunotherapy: Mapping the way. Nat. Med. 10, 475-480.
6. GUNZER, M., and GRABBE, S. (2001). Dendritic cells in cancer immunotherapy. Crit. Rev. Immunol. 21, 133-145.
7. HUNG, C.F., CHENG, W.F., HSU, K.F., CHAI, C.Y., HE, L., LING, M., and WU, T.C. (2001). Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res. 61, 3698-3703.
8. INABA, K., INABA, M., ROMANI, N., AYA, H., DEGUCHI, M., IKEHARA, S., MURAMATSU, S., and STEINMAN, R.M. (1992). Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176, 1693-1702.
9. JACOTOT, E., COSTANTINI, P., LABOUREAU, E., ZAMZAMI, N., SUSIN, S.A., and KROEMER, G. (1999). Mitochondrial membrane permeabilization during the apoptotic process. Ann. NY Acad. Sci. 887, 18-30.
10. JI, H., CHANG, E.Y., LIN, K.Y., KURMAN, R.J., PARDOLL, D.M., and WU, T.C. (1998). Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int. J. Cancer 78, 41-45.
11. JI, H., WANG, T.L., CHEN, C.H., PAI, S.I., HUNG, C.F., LIN, K.Y., KURMAN, R.J., PARDOLL, D.M., and WU, T.C. (1999). Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. Hum. Gene Ther. 10, 2727-2740.
12. JOHNSON, C.R., and JARVIS, W.D. (2004). Caspase-9 regulation: An update. Apoptosis 9, 423-427.
13. KIM, T.W., HUNG, C.F., BOYD, D., JUANG, J., HE, L., KIM, J.W., HARDWICK, J.M., and WU, T.C. (2003a). Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J. Immunol. 171, 2970-2976.
14. KIM, T.W., HUNG, C.F., LING, M., JUANG, J., HE, L., HARDWICK, J.M., KUMAR, S., and WU, T.C. (2003b). Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J. Clin. Invest. 112, 109-117.
15. KIM, T.W., HUNG, C.F., BOYD, D.A., HE, L., LIN, C.T., KAISERMAN, D., BIRD, P.I., and WU, T.C. (2004). Enhancement of DNA vaccine potency by coadministration of a tumor antigen gene and DNA encoding serine protease inhibitor-6. Cancer Res. 64, 400-405.
16. KIM, T.W., HUNG, C.F., LEE, J.H., HE, L., BOYD, D., HARDWICK, J.M., and WU, T.C. (2005). Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res. 65, 308-316.
17. KORSMEYER, S.J., WEI, M.C., SAITO, M., WEILER, S., OH, K.J., and SCHLESINGER, P.H. (2000). Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ, 7, 1166-1173.
18. LEBEDEVA, I., RANDO, R., OJWANG, J., COSSUM, P., and STEIN, C.A. (2000). Bcl-xL in prostate cancer cells: Effects of overexpression and down-regulation on chemosensitivity. Cancer Res. 60, 6052-6060.
19. LIN, K.Y., GUARNIERI, F.G., STAVELEY-O'CARROLL, K.F., LEVITSKY, H.I., AUGUST, J.T., PARDOLL, D.M., and WU, T.C. (1996). Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56, 21-26.
20. MARKIEWICZ, M.A., and KAST, W.M. (2004). Progress in the development of immunotherapy of cancer using ex vivo-generated dendritic cells expressing multiple tumor antigen epitopes. Cancer Invest. 22, 417-434.
21. MEDEMA, J.P., SCHUURHUIS, D.H., REA, D., VAN TONGEREN, J., DE JONG, J., BRES, S.A., LABAN, S., TOES, R.E., TOEBES, M., SCHUMACHER, T.N., BLADERGROEN, B.A., OSSENDORP, F., KUMMER, J.A., MELIEF, C.J., and OFFRINGA, R. (2001). Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: Differential modulation by T helper type 1 and type 2 cells. J. Exp. Med. 194, 657-667.
22. OPFERMAN, J.T., and KORSMEYER, S.J. (2003). Apoptosis in the development and maintenance of the immune system. Nat. Immunol. 4, 410-415.
23. RONCHESE, F., and HERMANS, I.F. (2001). Killing of dendritic cells: A life cut short or a purposeful death? J. Exp. Med. 194, F23-26.
24. RUSSELL, J.H., and LEY, T.J. (2002). Lymphocyte-mediated cytotoxicity. Ann. Rev. Immunol. 20, 323-370.
25. SCHULER, G., SCHULER-THURNER, B., and STEINMAN, R.M. (2003). The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15, 138-147.
26. SHEN, Z., REZNIKOFF, G., DRANOFF, G., and ROCK, K.L. (1997). Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J. Immunol. 158, 2723-2730.
27. TURTLE, C.J., and HART, D.N. (2004). Dendritic cells in tumor immunology and immunotherapy. Curr. Drug Targets 5, 17-39.
28. WANG, T.L., LING, M., SHIH, I.M., PHAM, T., PAI, S.I., LU, Z., KURMAN, R.J., PARDOLL, D.M., and WU, T.C. (2000). Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther. 7, 726-733.